Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Doris Wenning"'
Publikováno v:
European Journal of Cancer. 42:1623-1639
The ubiquitin-proteasome pathway is the major cellular degradative system for various proteins critical for proliferation, survival and homing of myeloma cells. Bortezomib is the first specific and reversible proteasome inhibitor for clinical applica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4665515c0d82136d336a333360153611
https://doi.org/10.1016/j.ejca.2006.02.015
https://doi.org/10.1016/j.ejca.2006.02.015
Autor:
Matthias Stelljes, Sarah Volpert, Martin Kropff, Joachim Kienast, Carsten Müller-Tidow, Guido Bisping, Frank Hilberg, Doris Wenning, Gerald Juergen Roth, Rolf M. Mesters, Martin Stefanic, Dirk Gustavus, Gerd Munzert, Wolfgang E. Berdel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(2)
Purpose: Novel drugs including targeted approaches have changed treatment paradigms for multiple myeloma (MM) and may also have therapeutic potential in the poor-prognosis t(4;14) subset; t(4;14) results in overexpressed and activated fibroblast grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932910e08e0f6082a145224afec4ae90
https://pubmed.ncbi.nlm.nih.gov/19147757
https://pubmed.ncbi.nlm.nih.gov/19147757
Autor:
Carsten Müller-Tidow, Doris Wenning, Rolf M. Mesters, Guido Bisping, Wolfgang E. Berdel, Joelle Tchinda, Matthias Stelljes, Hubert Serve, Frank Hilberg, Martin Kropff, Joachim Kienast, Christian Scheffold, Martin Stefanic, Sergey Bessonov, Britta Dreyer, Gerald Juergen Roth, Peter Liebisch, Gerd Munzert, Nicola Lang
Publikováno v:
Blood. 107(5)
In multiple myeloma (MM), both vascular endothelial (VEGF) and basic fibroblast growth factor (bFGF) promote tumor growth and survival. We have used the novel indolinone BIBF 1000 to study effects of simultaneous inhibition of VEGF, FGF and transform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2a6e12a784c487a2410789407cb268
https://pubmed.ncbi.nlm.nih.gov/16278310
https://pubmed.ncbi.nlm.nih.gov/16278310
Autor:
Wolfgang E. Berdel, Doris Wenning, Joelle Tchinda, Guido Bisping, Martin Kropff, Joachim Kienast, Sarah Volpert
Publikováno v:
Leukemia research. 29(5)
Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5c190321ddfcb7ff9eaa818130bd9e
https://pubmed.ncbi.nlm.nih.gov/15755512
https://pubmed.ncbi.nlm.nih.gov/15755512
Autor:
Teresa Padró, Doris Wenning, Matthias Kroger, Wolfgang E. Berdel, Rolf M. Mesters, Christian Scheffold, Berno Dankbar, R. Leo, Guido Bisping, Martin Kropff, Joachim Kienast
Publikováno v:
Blood. 101(7)
Myeloma cells express basic fibroblast growth factor (bFGF), an angiogenic cytokine triggering marrow neovascularization in multiple myeloma (MM). In solid tumors and some lymphohematopoietic malignancies, angiogenic cytokines have also been shown to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f02dcef587a86f3a15a4875bd5446b67
https://pubmed.ncbi.nlm.nih.gov/14527891
https://pubmed.ncbi.nlm.nih.gov/14527891
Autor:
Wolfgang E. Berdel, Guido Bisping, Gerald Juergen Roth, Martin Kropff, Joachim Kienast, Frank Hilberg, Doris Wenning, Gerd Munzert
Publikováno v:
Blood. 106:112-112
Novel antineoplastic agents have opened perspectives to more selective treatment of multiple myeloma (MM). Targets include FGFR3 or c-maf and VEGFR1 expressed in MM subgroups carrying t(4;14)(p16.4;q32) or t(14;16)(q32;q23), respectively. The t(4;14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88759b063ce6d23afafe814a20de6eb2
https://doi.org/10.1182/blood.v106.11.112.112
https://doi.org/10.1182/blood.v106.11.112.112
Publikováno v:
Blood. 104:4923-4923
Single agent bortezomib treatment at the dosage and schedule published by Richardson (2003) stabilizes disease in nearly 60% of patients with relapsed, refractory multiple myeloma (MM). However, only 35% of patients achieve an objective (≥ minor) r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c72097ccbd1b31c6ff3f662027bb8333
https://doi.org/10.1182/blood.v104.11.4923.4923
https://doi.org/10.1182/blood.v104.11.4923.4923
Publikováno v:
In Blood 15 October 2003 102(8):3072-3073